CB1 is found in 28% of breast carcinomas, with predominance in HER2+ tumors (14%), whereas CB2 is found in 72% of breast tumors, where it is again expressed predominantly in the HER2+ subtype (91%) [10]. Here, ERBB2 is linked to breast carcinoma.